Dublin, Nov. 17, 2017 -- The "Absorbent Nonwovens for Medical and Hygiene Textiles Applications" report has been added to Research and Markets' offering.
This report aims to give an overview of the use of absorptive nonwovens, issues over their continued use for the global population, and new innovations and technologies coming from both research bodies and manufacturers. New processes, composite materials and recycling solutions will be analysed, and an overview will be given of the current market leaders in the absorbent nonwovens field.
The use of nonwoven material in the hygiene and medical sectors is ever increasing, due to the extensive properties offered by nonwoven fabrics over their more traditional woven and knitted counterparts. Ageing populations and overweight and obese populations across the world are pushing more innovation and research into disposable medical and hygiene nonwoven products, in an attempt to find new ways of improving customer well-being and comfort. However, as concerns for the environment become heightened, companies must find new ways to adapt their products to meet increasingly tough standards.
Key Topics Covered:
Executive summary
1. Introduction
1.1. Nonwoven processing
1.2. Mechanism of absorbency in nonwovens
2. Absorbent nonwoven products
2.1. Application areas
2.2. Performance mechanisms
2.3. Other required performances
2.4. Why use nonwovens?
2.5. SAPs vs. wood pulp
3. Standards and testing methods for absorbent materials
3.1. laboratory testing method
3.2. Panel (consumer) testing need
4. Current commercialised products and key players
5. Innovations and new developments in industry
5.1. Fit, comfort and quality of life' improvements
5.2. Composite
5.3. Manufacture efficiency and new fibre technologies
5.4. Environmentally-friendly and biodegradable materials
5.5. Recycling
6. Academic research and innovation
6.1. Polymer modification and nanomaterials
6.2. Biocompatibility and environmentally-friendly materials
6.3. Recycling
6.4. Quality of life improvements and antibacterial components
6.5. Alternative SAP products
7. Conclusion and outlook
8. References
Companies Mentioned
- Abigo Medical AB
- Acelity
- Avgol
- BSN medical
- Barnhardt
- DSG International
- Dilo
- Drylock Technologies
- EAM engineering
- Essity (formerly SCA Hygiene products)
- Evonik
- Fibertex Nonwovens
- Fibertex Nonwovens
- First Quality Consumer Products
- Glatfelter
- Kimberley Clark Corporation
- Magic
- Medline Industries
- Paul Hartmann
- Polymer Group Inc. (Berry Plastics)
- Proctor & Gamble
- Suominen
- T J Beall
- Technical Absorbents
- Texol
- Texsus
- Unicharm
For more information about this report visit https://www.researchandmarkets.com/research/hrcr6d/absorbent
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Textiles, Medical Textiles


American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Anta Sports Expands Global Footprint With Strategic Puma Stake
Washington Post Publisher Will Lewis Steps Down After Layoffs
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 



